Matt Rosenberg, MD
Family Medicine · Jackson, MINPI 1730289711
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 38.3% of the total. Reporting peaked in 2023 at $142,196 and has fallen 53.2% since, to $66,558 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,399 payments — averaging $393.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$210K
- Astellas Pharma US Inc$113K
- Urovant Sciences Inc$89K
- Ferring Pharmaceuticals Inc.$44K
- OPKO Pharmaceuticals, LLC$29K
- Ferring Pharmaceuticals AS$20K
- plus $45K from 54 others
Across 7 payments — averaging $1334.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$8K
- Sumitomo Pharma America, Inc.$2K
What the payments were for
- Consulting fees$153,54328%
- Speaking & faculty fees$293,42553%
- Travel & lodging$81,47915%
- Food & beverage$21,5264%
- Education$720%
- Other$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$280,849
- Veozah$60,556
- NOCDURNA$36,988
- MYRBETRIQ$24,029
- FIRMAGON$12,336
- GENERAL BPH$9,606
- Rayaldee$9,000
- Natesto$7,595
- GENERAL - THERAPIES$925
- Quillivant$239
- QELBREE$222
- LumineticsCore$131
How this compares
$550,107 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $123,070 |
| EliquisApixaban | 127 | $116,324 |
| JardianceEmpagliflozin | 58 | $68,467 |
| XareltoRivaroxaban | 62 | $56,017 |
| FarxigaDapagliflozin Propanediol | 28 | $28,734 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $27,397 |
| MounjaroTirzepatide | 12 | $21,561 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $18,668 |
| JanuviaSitagliptin Phosphate | 13 | $14,424 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 56 | $12,508 |
| MyrbetriqMirabegron | 12 | $10,078 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 25 | $7,931 |
| DuleraMometasone/Formoterol | 11 | $6,823 |
| Tamsulosin Hcl | 235 | $6,253 |
| Atorvastatin Calcium | 360 | $5,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,293 | $123,07068 claims |
| PfizerEliquis | $1,228 | $116,324127 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $353 | $87,13586 claims |
| Johnson & JohnsonXarelto | $605 | $56,01762 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $618 | $47,836107 claims |
| AstraZenecaFarxiga | $617 | $28,73428 claims |
| Lilly USA, LLCMounjaro | $435 | $21,56112 claims |
| MerckJanuvia, Dulera | $380 | $21,24724 claims |
| Astellas Pharma US IncMyrbetriq | $112,807 | $10,07812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Jackson
- Channing SmithJackson$22K
- Stephen ArntzJackson$20K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.